Todd Peterson Net Worth

Todd Peterson biography

Dr. Todd Peterson, Ph.D. is Director of the Company. Dr. Peterson currently serves as Chief Scientific Officer at the Allen Institute in Seattle, Washington , overseeing science and technology strategy and operational, translational and growth initiatives to deliver on its impact mission. Prior to joining the Allen Institute in 2018, he served as Chief Technology Officer at Synthetic Genomics, Inc., a leader in synthetic biology and applied genomics technologies developing a robust portfolio of breakthrough solutions addressing major global issues. Prior to joining SGI, Dr. Peterson led genomics and synthetic biology R&D at Invitrogen/Life Technologies, a global leader in life science tools. Prior to Life Technologies, Dr. Peterson held research and development positions with increasing responsibilities and scope at Genicon Sciences, Trega Biosciences, Hybritech and Gen-Probe where he focused on technology research, product development and commercialization. Dr. Peterson was a postdoctoral fellow at the Max Planck Institute in Cologne, Germany after receiving his Ph.D. in Microbiology at the University of Southern California School of Medicine. He obtained his M.A. in Biological Sciences and B.A. in Molecular Biology and Biochemistry at the University of California, Santa Barbara .

What's Todd Peterson's mailing address?

Todd's mailing address filed with the SEC is 5005, McConnell Avenue, Del Rey, Los Angeles, Los Angeles County, California, 90066, United States.

Insiders trading at Armata Pharmaceuticals Inc

Over the last 5 years, insiders at Armata Pharmaceuticals Inc have traded over $0 worth of Armata Pharmaceuticals Inc stock and bought 24,083,630 units worth $91,149,692 . The most active insiders traders include Inc.Innoviva Strategic Oppo..., Inc. Innoviva,, and Michael S Perry. On average, Armata Pharmaceuticals Inc executives and independent directors trade stock every 122 days with the average trade being worth of $9,151,779. The most recent stock trade was executed by Inc.Innoviva Strategic Oppo... on 31 March 2022, trading 5,385,208 units of ARMP stock currently worth $26,926,040.

What does Armata Pharmaceuticals Inc do?

c3 jian is a well-capitalized, private, los angeles based biotechnology company advancing novel compounds that target unmet medical/dental needs related primarily to oral healthcare. the company's lead compound is a unique peptide drug against dental caries (i.e. tooth decay). the company’s lead compound started fda-regulated phase ii human clinical trials in early 2014. c3 jian's platform technology has also yielded peptides that can affect calcification processes, including not only tooth sensitivity but possibly hair and nail growth as well. the company has recently moved its operations to a new facility in marina del rey. the company was founded based on technology created in the laboratory of dr. wenyuan shi, chair of the department of oral biology at the university of california, los angeles school of dentistry. for more information about the company and to explore career opportunities at c3 jian please visit our webpage at www.c3-jian.com

Armata Pharmaceuticals Inc executives and stock owners

Armata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Todd R. Patrick MBA,
  Advisor & Director
• Dr. Brian Varnum Ph.D.,
  CEO & Director
• Steven R. Martin,
  Chief Financial Officer
• Robin Kramer,
  Director
• Mina Pastagia,
  Vice President - Clinical Development
• Sarah Schlesinger,
  Director
• Odysseas Kostas,
  Director
• Todd Peterson,
  Director
• Heather Jones,
  Medical Director
• Joseph Patti,
  Director
• Richard Bastiani,
  Director
• Duane Morris,
  Vice President - Operations
• Igor Bilinsky,
  Chief Operating Officer, Senior Vice President
• Steven Martin,
  Chief Financial Officer
• Todd Patrick,
  Chief Executive Officer, Director
• Brian Varnum,
  President, Chief Development Officer
• Erin Butler,
  VP of Fin. & Admin.
• Dr. Mina Pastagia M.D., MS,
  Sr. VP of Clinical Devel.
• Duane Alfred Morris BA,
  VP of Operations
• Dr. Wenyuan Shi Ph.D.,
  Co-Founder & Founding Scientist
• Deborah Birx,
  Chief Executive Officer
• Richard Rychlik,
  Corporate Controller and PFO
• Inc. Innoviva,,
  10% owner
• Richard Bear,
  Director
• Michael S Perry,
  Director
• H Stewart Parker,
  Director
• Jeremy Curnock Cook,
  Director
• Inc.Innoviva Strategic Oppo...,
  
• Jules Haimovitz,
  Director